Background Recently, mesenchymal stromal cells (MSCs) have gained recognition for their clinical utility in transplantation to induce tolerance and to improve/replace pharmacological immunosuppression. Cord blood (CB)-derived MSCs are particularly attractive for their immunological naivety and peculiar anti-inflammatory and anti-apoptotic properties. Objectives: The objective of this study was to obtain an inventory of CB MSCs able to support large-scale advanced therapy medicinal product (ATMP)-based clinical trials. Study design: We isolated MSCs by plastic adherence in a GMP-compliant culture system. We established a well-characterized master cell bank and expanded a working cell bank to generate batches of finished MSC(CB) products certified for clinical use. The MSC(CB) produced by our facility was used in approved clinical trials or for therapeutic use, following single-patient authorization as an immune-suppressant agent. Results: We show the feasibility of a well-defined MSC manufacturing process and describe the main indications for which the MSCs were employed. We delve into a regulatory framework governing advanced therapy medicinal products (ATMPs), emphasizing the need of stringent quality control and safety assessments. From March 2012 to June 2023, 263 of our Good Manufacturing Practice (GMP)-certified MSC(CB) preparations were administered as ATMPs in 40 subjects affected by Graft-vs.-Host Disease, nephrotic syndrome, or bronco-pulmonary dysplasia of the newborn. There was no infusion-related adverse event. No patient experienced any grade toxicity. Encouraging preliminary outcome results were reported. Clinical response was registered in the majority of patients treated under therapeutic use authorization. Conclusions: Our 10 years of experience with MSC(CB) described here provides valuable insights into the use of this innovative cell product in immune-mediated diseases.
SARS-CoV-2 infection triggers respiratory inflammation with potentially fatal systemic effects. Mesenchymal stromal/stem cells (MSCs) are promising for treating severe COVID-19 due to their anti-inflammatory and regenerative capacities. This study investigates the effects of allogeneic MSCs in severe COVID-19 pneumonia. In the phase I/IIa RESCAT trial (May 2021-Feb 2022), patients with severe COVID-19 pneumonia received two intravenous MSC infusions and were compared to a control group (CTRL). To assess cytokine and biomarker responses, the MSC group was matched 1:2 with standard care patients (mCTRL) by age, gender, BMI, and PaO2/FiO2 (Nov 2020-Feb 2021). Random-effects linear regression evaluated cytokine and biomarker trends over time between MSC and control groups. Seventeen patients (MSC = 5, CTRL = 2, mCTRL = 10) were analyzed. Two MSC infusions were feasible and safe, with all patients discharged on average 15 ± 3.7 days postsecond infusion. While IL1RA and IL18 levels significantly increased in CTRL-mCTRL patients (P = 0.044 and P = 0.032), MSC treatment averted these rises, showing a distinct trajectory, particularly for IL1RA. MSC treatment also reduced IL6 levels compared to CTRL-mCTRL, while both groups showed similar reductions in Long pentraxin. Furthermore, MSC infusions prevented the neurofilament light chain surge observed in CTRL patients. MSC in COVID-19 patients resulted safe and feasible, effectively modulating inflammatory cytokines, in particular mitigating brain damage related biomarker, suggesting both reduced inflammation and a potential neurological protection.